NasdaqGS · Biotechnology

Dyne Therapeutics (DYN)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+51.0%

$39.40 average target

$26.10+0.12 (+0.5%)Latest market snapshot · Yahoo Finance

Market cap$4.87B

Cash$898.5M

Quarterly burn$130.3M

Pipeline assets3

Short float15.0%

Latest coverage

News & Press Releases

External sources

Aug 20, 2026

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire

Jul 30, 2026

RBC Raises Price Target on Dyne Therapeutics to $35 From $30, Keeps Outperform, Speculative RiskMT Newswires

Jul 28, 2026

Dyne Therapeutics Receives FDA Clearance to Start Trial of Muscle Disease TreatmentMT Newswires

Continue with BioPharma ProUnlock 3 more recent stories and press releases.

Unlock Pro

Company profile

About Dyne Therapeutics

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.